HomeProductsBuilding BlocksHeterocyclic ScaffoldsAromatic HeterocyclesLorecivivint
Chemical structure of CAS 1467093-03-3

Lorecivivint

CAS No.1467093-03-3
MDL No.N/A
MFC29H24FN7O
MW505.50
InChI KeyAQDWDWAYVBQMAM-UHFFFAOYSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1467093-03-3
Product NameLorecivivint
Heavy Atom Count38Rotatable Bond Count6
Atom Stereo Count0Bond Stereo Count0
HBA5HBD3
TPSA112.240 ŲCharge0
Exact Mass505.20264Complexity1804.01
pKa9.247XLogP6.354

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

Osteoarthritis and cartilage • Vol. 27, Issue 9 • 2019
PMID: 31132406DOI: 10.1016/j.joca.2019.05.006

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

Osteoarthritis and cartilage • Vol. 26, Issue 1 • 2018
PMID: 28888902DOI: 10.1016/j.joca.2017.08.015

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Osteoarthritis and cartilage • Vol. 25, Issue 10 • 2017
PMID: 28711582DOI: 10.1016/j.joca.2017.07.006

Documentation